Hypochondroplasia (FGFR3) Gene Mutation Analysis
Hypochondroplasia (HCP) is a skeletal dysplasia characterized by short extremities and macrocephaly. Approximately seventy percent of cases are inherited as an autosomal dominant disorder caused by mutations in the fibroblast growth factor receptor 3 (FGFR3) gene. FGFR3 codes for a transmembrane protein and is an inhibitor of bone growth so that mutations lead to overexpression by way of a tyrosine kinase. Over twenty mutations of FGFR3 have been identifed in HCP. Of the inherited disproportionate short stature syndromes it is the most common. Patients who are homozygous are usually stillborn or die shortly after birth.
Two FGFR3 mutations (c.1620C>A and c.1620C>G) result in a lysine-for-asparagine substitution at codon 540 (p.Asn540Lys) in exon 10 and have been associated with hypochondroplasia. These mutations are responsible for alterations in the process of endochondral ossification in long bones. The FGFR3 gene is present at the distal region of the short arm of chromosome 4 (4p16.3). Compound heterozygotes for N540K/achondroplasia mutation have a severe skeletal phenotype and potential for significant medical problems. HCP is the mildest phenotype among a group of FGFR3-associated skeletal dysplasias affecting long bone growth.
Clinical features are related to skeletal abnormalities composed of mild short stature in preschool age, disproportionately short proximal (rhizomelia) or middle (mesomelia) segments of the extremities compared with the length of the trunk, mild bow legs (genu varum), lumbar lordosis, and in some cases macrocephaly and mental retardation.
Genetic testing for FGFR3 mutations (c.1620C>A and c.1620C>G) are the most commonly used genetic tests for confirmation of disease.
- Confirmatory diagnostic testing for hypochondroplasia
- Prenatal screening for carriers
- Heterozygous for either the c.1620C>A or c.1620C>G mutation, or compound heterozygote confirms the diagnosis of hypochondroplasia
- When neither the c.1620C>A nor the C.1620C>G mutation is present, the risk for hypochondroplasia is reduced but not eliminated
Negative for mutations analyzed (Mutation not detected).
Whole blood EDTA (lavender top tube) or ACD (blue top tube).
Stability
- Ambient: 3-5 days
- Refrigerated: 7-14 days
- Ann NY Acad Sci. 1996 Jun 8;785:182-7. [PMID: 8702125]
- Am J Med Genet A. 2010 Jan;152A(1):245-55. [PMID: 20034074]
- Atlas of genetic diagnosis and counseling (Humana press). 2006:517-520.
- Am J Med Genet A. 2011 Oct;155A(10):2426-35. [PMID: 21910223]
- Bookshelf ID: NBK1477 [PMID: 20301650]